Sarclisa यूरोपीय संघ - स्लोवाक - EMA (European Medicines Agency)

sarclisa

sanofi winthrop industrie - isatuximab - viacnásobný myelóm - antineoplastické činidlá - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Oxytocin Ferring-Léčiva 5 IU स्लोवाकिया - स्लोवाक - ŠÚKL (Štátny ústav pre kontrolu liečiv)

oxytocin ferring-léčiva 5 iu

ferring-léčiva, a.s., Česká republika - oxytocín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Oxytocin Ferring-Léčiva 2 IU स्लोवाकिया - स्लोवाक - ŠÚKL (Štátny ústav pre kontrolu liečiv)

oxytocin ferring-léčiva 2 iu

ferring-léčiva, a.s., Česká republika - oxytocín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)